首页 TrovaGene(usTROV)-基本信息

TrovaGene(usTROV)-基本信息

日报更新时间:

周报更新时间:01-23 11:54

行情信息

今开价:

最高价:

成交量:

昨收价:

最低价:

最新价:

行情图标
概要信息

英文名称:TrovaGene


简介:Trovagene, Inc.是一家出于发展阶段的分子诊断公司,专注由专有产权的诊断技术的开发和市场推广,这种技术在各种医学诊所用于患者/疾病的扫描和监视


电话:1-858-9527570


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Trovagene公司主要候选药物——PCM-075是Polo-like激酶1选择性三磷酸腺苷竞争性抑制剂。PCM-075正处于急性髓性白血病(AML)的 Ib/II 期临床试验中,并已完成晚期实体瘤的 I 期临床试验。PCM-075也处于多个临床前研究中,与大约10种化疗药物和目标药物结合用于血液和实体肿瘤癌症,包括:Zytiga(醋酸阿比特龙); Beleodaq(belinostat); Quizartinib(AC220),一种开发阶段的FLT3抑制剂; 和Velcade(硼替佐米)在AML,转移性去势抵抗性前列腺癌和其他血液和实体肿瘤癌症。Trovagene, Inc.主要服务于制药公司和第三方实验室。

交易日期 交易人 职位 类型 交易份额 价格
2019-06-30 Erlander (Mark) Officer Buy 1250 --
2019-06-30 Erlander (Mark) Officer Sell 461 --
2019-03-31 Erlander (Mark) Officer Buy 1250 --
2019-03-31 Erlander (Mark) Officer Sell 459 --
2019-01-01 Erlander (Mark) Officer Sell 698 --
2019-01-01 Erlander (Mark) Officer Buy 1563 --
2018-12-31 Erlander (Mark) Officer Sell 3035 --
2018-12-31 Erlander (Mark) Officer Buy 7500 --
2018-09-30 Erlander (Mark) Officer Buy 7500 --
2018-09-30 Erlander (Mark) Officer Sell 2731 --
2018-06-19 Markin (Rodney S) Director Buy 41200 0.85
2018-06-07 Brancaccio (John P) Director Buy 10000 0.80
2018-06-07 Tennant (Stanley) Director Buy 10000 0.80
2018-01-29 Welch (William J) Chief Executive Officer Sell 62010 --
2018-01-29 Welch (William J) Chief Executive Officer Buy 130000 --
2018-01-29 Erlander (Mark) Officer Buy 90000 --
2018-01-29 Erlander (Mark) Officer Sell 42930 --
2018-01-01 Welch (William J) Chief Executive Officer Buy 50000 --
2018-01-01 Tennant (Stanley) Director Buy 16667 --
2018-01-01 Markin (Rodney S) Director Buy 16667 --
2018-01-01 Erlander (Mark) Officer Sell 9558 --
2018-01-01 Adams (Thomas H. Jr., Ph.D.) Director Buy 16667 --
2018-01-01 Brancaccio (John P) Director Buy 16667 --
2018-01-01 Billings (Paul R) Director Buy 16667 --
2018-01-01 Welch (William J) Chief Executive Officer Sell 25487 --

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Northern Trust Investments Inc 4487 0.09% 11 0.25% 2019-07-31
Fidelity Management & Research Company 16156 0.31% -- -- 2019-07-31
Geode Capital Management, LLC 16581 0.32% 16581 -- 2019-03-31
Vassalluzzo Scott J 18679 0.36% 18679 -- 2019-03-31
Dimensional Fund Advisors LP 20519 0.39% -- -- 2019-07-31
Dimensional Fund Advisors, Inc. 20519 0.39% 20519 -- 2019-03-31
Vanguard Group Inc 67764 1.29% 9417 16.14% 2019-03-31
Renaissance Technologies Corp 160221 3.05% 45759 39.98% 2019-03-31
Vanguard Investments Australia Ltd 245636 4.68% -- -- 2019-07-31
BlackRock Inc 5546 0.11% 5546 -- 2019-03-31
Hudson Canyon Investment Counselors LL 240 -- 240 -- 2019-03-31
Bank of Montreal 2600 0.05% 2350 940.00% 2019-03-31
BlackRock Advisors (UK) Ltd 348 0.01% 1 0.29% 2019-03-31
Barclays PLC 348 0.01% 1 0.29% 2019-03-31
BlackRock 527 0.01% -1 -0.19% 2019-07-31
BlackRock Asset Management Canada Ltd 752 0.01% -- -- 2019-07-31
CapTrust Financial Advisors 785 0.01% -- -- 2019-03-31
UBS Group AG 794 0.02% -5825 -88.00% 2019-03-31
FNY Investment Advisers, LLC 2000 0.04% 2000 -- 2019-03-31
BMO Harris Bank NA 2600 0.05% 2350 940.00% 2019-03-31
Wells Fargo & Co 517 0.01% 258 99.61% 2018-12-31
Mellon Investments Corporation 436 0.01% 80 22.47% 2019-06-30
Bank of America Corporation 417 0.01% 417 -- 2018-12-31
Morgan Stanley - Brokerage Accounts 580 0.01% 202 53.44% 2018-12-31
Susquehanna Financial Group, LLLP 171956 3.28% 122332 246.52% 2018-12-31
Susquehanna International Group, LLP 171956 3.28% 122332 246.52% 2018-12-31
Dowling & Yahnke Inc 62267 1.19% -- -- 2018-12-31
Northern Trust Investments N A 26521 0.51% -- -- 2018-12-31
Northern Trust Corp 26521 0.11% -- -- 2018-12-31
TWO SIGMA SECURITIES, LLC 14825 0.06% -1175 -7.34% 2018-09-30
Citadel Advisors Llc 18260 0.08% -5253 -22.34% 2018-09-30
Security National Bank 41200 0.17% -- -- 2018-09-30
Sabby Management LLC 153638 0.64% -596912 -79.53% 2018-09-30
Elkhorn Partners Limited Partnership 89168 0.37% -- -- 2018-09-30
Two Sigma Investments LLC 37190 0.15% 37190 -- 2018-09-30
Vanguard 9243 0.04% -157 -1.67% 2018-12-31
BNY Mellon Asset Management North America Corporation 7610 0.03% 6160 424.83% 2018-11-30
UBS Securities LLC 14436 0.06% 12603 687.56% 2018-06-30
BlackRock Institutional Trust Company NA 32147 0.14% -- -- 2018-06-30
CVI Holdings LLC 307445 1.34% 307445 -- 2018-06-30
Goldman Sachs Group Inc 15013 0.07% -345 -2.25% 2018-03-31
Raymond James & Associates 22000 0.10% -1000 -4.35% 2018-03-31
BNY Mellon Investment Management 26395 0.11% -- -- 2018-03-31
Bank of New York Mellon Corp 31953 0.14% -24535 -43.43% 2018-03-31
California Public Employees Retrmnt Sys 77200 0.34% -- -- 2018-03-31
Bigger Capital Fund, LP 1146800 6.48% -81033 -6.60% 2018-08-17
Ayrton Capital LLC 739922 1.25% 739922 -- 2018-06-08
Meeder Asset Management Inc 6610 0.04% 2544 62.57% 2018-08-31
Mellon Capital Management Corporation 1971 0.01% 1 0.05% 2018-06-30
Guggenheim Funds Investment Advisors LLC 4531 0.02% -- -- 2018-09-14
BMO Asset Management Inc 1876 0.01% 1876 -- 2018-06-30
J.P. Morgan Securities Inc 68 -- -- -- 2018-06-30
Morgan Stanley & Co Inc 292 -- 232 386.67% 2018-06-30
Merrill Lynch & Co Inc 486 -- 486 -- 2018-06-30
Morgan Stanley Smith Barney LLC 42 -- 42 -- 2018-06-30
Wells Fargo Advisors, LLC 259 -- 217 516.67% 2018-06-30
USAA Asset Management Company 460 -- 460 -- 2018-06-30
Vanguard Group Inc. 509 -- 1 0.20% 2018-06-30
BlackRock Fund Advisors 4268 0.02% 85 2.03% 2018-08-23
Intracoastal Capital LLC 2666666 -- 2666666 -- 2017-12-15
Heights Capital Management Inc 2593218 -- 2593218 -- 2017-12-31
Prospera Financial Services Inc 127350 -- 1000 0.79% 2017-12-31
Messner Smith Theme Value Inv Mgmt Ltd 23850 -- -3075 -11.42% 2017-12-31
CAMBRIDGE Invest RESEARCH ADVISORS, INC. 21400 -- -900 -4.04% 2017-12-31
Millennium Management LLC 111354 0.21% -230989 -67.47% 2017-12-31
Princeton Capital Management Inc 17070 0.04% -18000 -51.33% 2017-09-30
Virtu Financial LLC 79050 0.21% 79050 -- 2017-09-30
HighTower Advisors, LLC 25500 0.06% -40100 -61.13% 2017-09-30
Goldman, Sachs & Co. 14902 0.04% -263284 -94.64% 2017-09-30
Davidson D A & Co 159668 0.42% -21000 -11.62% 2017-09-30
BARCLAYS BANK PLC, HONG KONG 25000 0.08% -- -- 2017-06-30
Christian Brothers Inv Srvc Inc 17017 0.06% -- -- 2016-09-30
Windsor Financial Group Llc 62500 0.20% -- -- 2017-06-30
Element Capital Management LLC 131637 0.42% 131637 -- 2017-06-30
Sunrise Partners LLC 82500 0.27% 82500 -- 2017-06-30
State Street Corp 24800 0.08% -410107 -94.30% 2017-06-30
Bridger Management Llc 2460626 8.04% -829961 -25.22% 2016-11-11
Morgens, Waterfall, Vintiadis & Co. Inc 300000 0.98% -- -- 2016-09-30
TIAA-CREF Investment Management LLC 87532 0.29% -51436 -37.01% 2016-09-30
BlackRock Advisors LLC 112917 0.37% -2515 -2.18% 2016-09-30
California State Teachers Retirement Sys 59677 0.20% 600 1.02% 2016-09-30
Blue Planet Investment Mgmnt 124468 0.40% -- -- 2017-01-31
Gabriele Cerrone 1852438 10.00% 10484799 0.10% 1999-11-30
Bridger Management,LLC 3150587 10.00% 17832322 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
USAA Extended Market Index Fund 76 -- -- -- 2019-06-30
BlackRock Extended Equity Market 527 0.01% -1 -0.19% 2019-06-30
Vanguard Balanced Index Fund 3233 0.06% -- -- 2019-06-30
DFA US Micro Cap Portfolio 4000 0.08% -- -- 2019-05-31
NT Ext Equity Market Index Fund - L 4018 0.08% -- -- 2019-06-30
DFA Tax Managed US Small Cap Portfolio 7600 0.14% -- -- 2019-06-30
DFA US Targeted Value Portfolio 8919 0.17% -- -- 2019-05-31
Vanguard Extended Market Index Fund 36281 0.69% -- -- 2019-06-30
Vanguard Total Stock Market Index Fund 245636 4.68% -- -- 2019-06-30
Fidelity 345 0.01% -- -- 2019-06-30
NT Extended Equity Market Idx Fund - NL 217 -- -- -- 2019-06-30
NT US Market Cap Index Fund - Lending 84 -- -- -- 2019-06-30
State Street U.S. Extended Market Index 143 -- -- -- 2019-07-31
NT Ext Equity Mkt Fd - DC - NL 155 -- 11 7.64% 2019-06-30
iShares Core S&P US Total Market ETF 188 -- -- -- 2019-05-30
iShares Core Balanced ETF Portfolio 188 -- -- -- 2019-05-30
iShares Core MSCI AllCntry Wld exCan ETF 188 -- -- -- 2019-05-30
iShares Core Growth ETF Portfolio 188 -- -- -- 2019-05-30
iShares Core S&P Total US Stock Mkt ETF 188 -- -- -- 2019-07-30
BNYM Mellon SL Mkt Completion Fd 99 -- -237 -70.54% 2019-03-31
NT Ext Equity Mkt Idx Fd - DC - NL 155 -- 11 7.64% 2019-06-30
BNYM Mellon NSL Mkt Completion Fd Instl 337 0.01% 317 1585.00% 2019-03-31
BNYM Mellon SL Market Completion Fund 99 -- -237 -70.54% 2019-03-31
Vanguard US Equity Index Fund -- -- -509 -100.00% 2018-12-31
Meeder Spectrum Fund -- -- -6610 -100.00% 2018-09-30
Invesco Wilshire Micro-Cap ETF -- -- -772 -100.00% 2019-02-22
BNY Mellon Market Completion Fund 120 -- -514 -81.07% 2018-12-31
Master Extended Market Index Series -- -- -5524 -100.00% 2018-02-28
The Vanguard Total Stock Market Index 9243 0.04% -157 -1.67% 2017-11-30
JHVIT Total Stock Market Index Tr 1241 0.01% -- -- 2017-07-31
USAA Extended Market Index 460 -- -- -- 2018-07-31
iShares Core S&P Total US Stock Mkt 1128 0.01% -- -- 2018-09-12
Vanguard Total Stock Mkt Idx 1176 0.01% -- -- 2018-07-31
BNY Mellon EB DL Mkt Completion 1971 0.01% 1 0.05% 2018-06-30
Vanguard Balanced Index Inv 2468 0.01% -- -- 2018-07-31
Vanguard Extended Market Idx Inv 192747 1.09% 157638 449.00% 2018-07-31
Meeder Spectrum 6610 0.04% 2544 62.57% 2018-08-31
Wilshire Micro-Cap ETF 4531 0.02% -- -- 2018-09-14
BlackRock Extended Equity Market K 3140 0.02% 85 2.78% 2018-06-30
Fidelity Spartan 2821 0.02% -- -- 2018-07-31
SSgA U.S. Total Market Index Fd Class I 2885 0.07% -188 -6.12% 2017-12-31
BNY Mellon Market Completion Fund UC1 7610 0.16% 6160 424.83% 2018-03-31
Nuveen Small Cap Index I 1764 0.07% -- -- 2017-03-31
Christian Bros CUIT Small Cap Eqty Idx B 17017 0.06% -- -- 2016-09-30
Vantagepoint Broad Market Index I 4449 0.01% -- -- 2016-09-30
Vantagepoint Mid/Small Company Index I 3916 0.01% -- -- 2016-09-30
Schwab Instl Small Cap Tr Fd-Instl 81 -- 13 19.12% 2016-12-31
iShares Russell 2000 Growth 202063 0.73% -- -- 2017-02-07
iShares Micro-Cap 69537 0.25% -- -- 2017-02-07
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 71218 0.23% 402 0.57% 2016-12-31
CREF Stock R1 60138 0.20% -- -- 2016-12-31
AXA 2000 Managed Volatility K 40269 0.13% -- -- 2016-11-30
BlackRock Russell 2000 41330 0.13% 2299 5.89% 2016-12-31
The Vanguard Russell 2000 Growth Index 41222 0.13% -- -- 2016-12-31
TIAA-CREF Small-Cap Blend Idx Inst 37686 0.12% -- -- 2016-12-31
Schwab Small Cap Index 35347 0.12% -- -- 2016-12-31
BlackRock Russell 2500 30829 0.10% 48 0.16% 2016-12-31
iShares Russell 2000 Value 22728 0.08% -90 -0.39% 2017-02-07
Carnegie Global Healthcare 328584 1.10% -- -- 2015-10-31
Turner Medical Sciences Long/Short 183630 0.60% -- -- 2015-09-30
CREF Stock Account 182003 0.60% 17000 10.30% 2015-09-30
Fidelity Spartan® Extended Mkt Indx Fd 105483 0.40% 5294 5.30% 2015-09-30
The Vanguard - Russell 2000 Grwth Idx CF 50322 0.20% -- -- 2015-10-31
AXA 2000 Managed Volatility Portfolio 40269 0.10% -- -- 2015-09-30
BlackRock Russell 2000® Index Non-Lendable Fund 38746 0.10% 14241 58.10% 2015-09-30
Schwab Small Cap Index Fund® 35347 0.10% -- -- 2015-09-30
Fidelity Spartan® Total Market Idx Fund 33847 0.10% -- -- 2015-09-30
iShares Russell 2000 (AU) 466375 2.10% -588 -0.10% 2015-11-19

Rodney S. Markin Rodney S. Markin founded LAB-InterLink. Currently, Dr. Markin is Chairman of PerceptiMed, Inc. He is also Chief Operating Officer at the University of Nebraska and on the board of 6 other companies. Dr. Markin previously held the position of Chairman, President & Chief Executive Officer at UNMC Physicians, Chairman for Transgenomic, Inc., Chief Executive Officer at LAB-InterLink and Chief Technology Officer at the University of Nebraska Medical Center. He received an undergraduate degree from Nebraska Wesleyan University, a doctorate from the University of Nebraska Medical Center and a doctorate from The University of Nebraska-Lincoln.
John P. Brancaccio John P. Brancaccio is on the board of Tamir Biotechnology, Inc. and 4 other companies. In his past career Mr. Brancaccio held the position of Chief Operating & Financial Officer for Eline Entertainment Group, Inc., Chief Financial Officer at Orchestra Medical Ventures LLC, Chief Financial Officer, Secretary & Treasurer of Memory Pharmaceuticals Corp. and Chief Financial Officer at Accelerated Technologies, Inc. Mr. Brancaccio received an undergraduate degree from Seton Hall University.
Rodney S. Markin Dr. Karsten Schmidt is Chief Technology Officer at TrovaGene, Inc. and Head-Administration at Zentrum f�0�1�0�4r Foren in der Grafischen Datenverarbeitung eV. Dr. Schmidt was previously employed as Vice President-Business Development by Sequenom, Inc. He received his doctorate degree from the University of Bonn.
Thomas H. Adams Founder of Gen-Probe, Inc. and Genta, Inc., Thomas H. Adams is a businessperson who has been at the helm of 7 different companies and presently holds the position of Chairman & Chief Executive Officer of TrovaGene, Inc. Dr. Adams is also on the board of ContraVir Pharmaceuticals, Inc. and Gensignia Life Sciences, Inc. In his past career Dr. Adams was Executive Chairman of Clearbridge Biophotonics, Inc., Chief Executive Officer for Genta, Inc., Chairman & Chief Executive Officer for Leucadia Technologies, Inc., Chairman & Chief Executive Officer at Gen-Probe, Inc., Chairman & Chief Executive Officer at Iris Molecular Diagnostics, Inc., President at IRIS Personalized Medicine, Inc., Director-Research & Development at Baxter Laboratories, Inc., Director & Chief Technology Officer at Iris International, Inc. and Chief Technology Officer at Hybritech, Inc. Thomas H. Adams received a doctorate from the University of California, Riverside.
Gary S. Jacob Gary S. Jacob is a businessperson who has been at the helm of 7 different companies and currently holds the position of Chairman of ContraVir Pharmaceuticals, Inc., Chief Executive Officer & Director at Immuron Ltd. and President & Chief Executive Officer of Synergy Pharmaceuticals LLC. Dr. Jacob is also on the board of TrovaGene, Inc. In the past Dr. Jacob held the position of Chairman for Synergy Pharmaceuticals, Inc., Chairman of Synergy DE, President, Chief Executive & Scientific Officer at Callisto Pharmaceuticals, Inc., President, Chief Executive Officer & Director at Pawfect Foods, Inc., Glycobiology Director at G.D. Searle & Co. Ltd., Director-Functional Genomics at Monsanto Co. and Manager-Searle Glycobiology Group at the University of Oxford. Gary S. Jacob received a doctorate from the University of Wisconsin and an undergraduate degree from the University of Missouri.
Rodney S. Markin Dr. Karsten Schmidt is Chief Technology Officer at TrovaGene, Inc. and Head-Administration at Zentrum f�0�1�0�4r Foren in der Grafischen Datenverarbeitung eV. Dr. Schmidt was previously employed as Vice President-Business Development by Sequenom, Inc. He received his doctorate degree from the University of Bonn.
Mark Erlander Presently, Mark Erlander is Chief Scientific Officer at TrovaGene, Inc. In his past career he was Chief Scientific Officer at Biotheranostics, Inc., Chief Scientific Officer of Arcturus, Inc., Chief Scientific Officer at Gensignia Life Sciences, Inc., Principal at Johnson & Johnson and Assistant Professor at The Scripps Research Institute. He received a doctorate from the University of California, Los Angeles, a graduate degree from Iowa State University and an undergraduate degree from the University of California, Davis.
Paul R. Billings Dr. Paul R. Billings is a Chief Medical Officer & Senior VP-Medical Affairs at Natera, Inc., an Independent Director at MetaStat, Inc., an Independent Director at TrovaGene, Inc., a Director & Chief Medical Officer at Fabric Genomics, Inc., an Executive Chairman at Melanoma Diagnostics, Inc., an Executive Chairman at Signature Genomics Laboratories LLC and a Professor at University of California, Berkeley. He is on the Board of Directors at MetaStat, Inc., TrovaGene, Inc., Applied Immunology, Inc., Aueon, Inc., Cynvenio Biosystems, Inc., DecisionQ Corp., Mission Bio, Inc., OmniSeq, Inc., PAX Neuoscience, Inc. and Fabric Genomics, Inc. Dr. Billings was previously employed as an Independent Director by Rennova Health, Inc., a Medical Director-IMPACT Program by Thermo Fisher Scientific, Inc., an Independent Director by Ancestry.com, Inc., a Chief Medical Officer by Life Technologies Corp., a President & Executive Officer by Cellective Dx Corp., a Co-Founder by CBR Systems, Inc., a Chairman by Biological Dynamics, Inc., a Co-Founder by GeneSage, Inc., a SVP-Corporate Development & Strategy by Laboratory Corp. of America Holdings, and a Vice President-Life Sciences & Clinical Affairs by Wipro Ltd. He also served on the board at CollabRx, Inc., Cyntellect, Inc., Celldex Therapeutics, Inc., Lipomics Technologies, Inc., PAX Scientific, Inc., BioScale, Inc. and SGL Carbon LLC. He received his undergraduate degree from the University of California, a doctorate degree from Harvard University and a doctorate degree from Harvard Medical School.
Rodney S. Markin Rodney S. Markin founded LAB-InterLink. Currently, Dr. Markin is Chairman of PerceptiMed, Inc. He is also Chief Operating Officer at the University of Nebraska and on the board of 6 other companies. Dr. Markin previously held the position of Chairman, President & Chief Executive Officer at UNMC Physicians, Chairman for Transgenomic, Inc., Chief Executive Officer at LAB-InterLink and Chief Technology Officer at the University of Nebraska Medical Center. He received an undergraduate degree from Nebraska Wesleyan University, a doctorate from the University of Nebraska Medical Center and a doctorate from The University of Nebraska-Lincoln.
Rodney S. Markin Rodney S. Markin founded LAB-InterLink. Currently, Dr. Markin is Chairman of PerceptiMed, Inc. He is also Chief Operating Officer at the University of Nebraska and on the board of 6 other companies. Dr. Markin previously held the position of Chairman, President & Chief Executive Officer at UNMC Physicians, Chairman for Transgenomic, Inc., Chief Executive Officer at LAB-InterLink and Chief Technology Officer at the University of Nebraska Medical Center. He received an undergraduate degree from Nebraska Wesleyan University, a doctorate from the University of Nebraska Medical Center and a doctorate from The University of Nebraska-Lincoln.
Stanley Neal Tennant Stanley Neal Tennant occupies the position of President at Five Star Management, Inc. He is also on the board of Oak Ridge Financial Services, Inc., Bank of Oak Ridge (North Carolina) and TrovaGene, Inc. He received a doctorate from Wake Forest School of Medicine.
Athena Countouriotis Athena Countouriotis is on the board of TrovaGene, Inc., Iovance Biotherapeutics, Inc. and NuMedii, Inc. and President, Chief Executive Officer & Director at Turning Point Therapeutics, Inc. She previously occupied the position of Chief Medical Officer & Senior Vice President at Adverum Biotechnologies, Inc., Chief Medical Officer & Senior Vice President of Halozyme Therapeutics, Inc., Director-Oncology Global Clinical Research at Bristol-Myers Squibb Co., Associate Medical Director at CTI BioPharma Corp. and Chief Medical Officer of Ambit Biosciences Corp. She received a doctorate from Tufts University School of Medicine and an undergraduate degree from the University of California, Los Angeles.
Rodney S. Markin Dr. Karsten Schmidt is Chief Technology Officer at TrovaGene, Inc. and Head-Administration at Zentrum f�0�1�0�4r Foren in der Grafischen Datenverarbeitung eV. Dr. Schmidt was previously employed as Vice President-Business Development by Sequenom, Inc. He received his doctorate degree from the University of Bonn.
Rodney S. Markin Dr. Karsten Schmidt is Chief Technology Officer at TrovaGene, Inc. and Head-Administration at Zentrum f�0�1�0�4r Foren in der Grafischen Datenverarbeitung eV. Dr. Schmidt was previously employed as Vice President-Business Development by Sequenom, Inc. He received his doctorate degree from the University of Bonn.
Athena Countouriotis Athena Countouriotis is on the board of TrovaGene, Inc., Iovance Biotherapeutics, Inc. and NuMedii, Inc. and President, Chief Executive Officer & Director at Turning Point Therapeutics, Inc. She previously occupied the position of Chief Medical Officer & Senior Vice President at Adverum Biotechnologies, Inc., Chief Medical Officer & Senior Vice President of Halozyme Therapeutics, Inc., Director-Oncology Global Clinical Research at Bristol-Myers Squibb Co., Associate Medical Director at CTI BioPharma Corp. and Chief Medical Officer of Ambit Biosciences Corp. She received a doctorate from Tufts University School of Medicine and an undergraduate degree from the University of California, Los Angeles.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐